Filing Analysis
Anebulo Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the quarter ended December 31, 2025, and provided a general business update.
🚩 Red Flags
- Interim CFO role suggests potential recent turnover in financial leadership, though no specific departure was detailed in this text.
📋 Key Facts
- Report date: February 12, 2026
- Reporting period: Quarter ended December 31, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Richard Anthony Cunningham is serving as both CEO and Interim CFO.
Anebulo Pharmaceuticals, Inc. has announced the voluntary delisting of its common stock from the Nasdaq Capital Market and the subsequent deregistration of its securities with the SEC. This move is intended to terminate all periodic reporting obligations under the Securities Exchange Act of 1934.
🚩 Red Flags
- Voluntary delisting and deregistration typically indicates a move toward becoming a private company or a significant reduction in liquidity/transparency.
- Termination of reporting obligations (Form 15) removes public access to financial data, making it difficult for investors to track performance.
- The transition from a Nasdaq-listed entity to a non-reporting entity is often a precursor to insolvency or a complete shift in corporate structure.
📋 Key Facts
- Board approved voluntary delisting from Nasdaq on February 5, 2026.
- Company intends to file Form 25 (Notification of Removal from Listing) on or about February 17, 2026.
- Delisting is expected to become effective on February 27, 2026.
- Company intends to file Form 15 on or about February 27, 2026, citing fewer than 300 shareholders of record.
- Upon filing Form 15, the company's obligation to file periodic reports with the SEC will be suspended.
Anebulo Pharmaceuticals announced the final results of its tender offer to repurchase up to 300,000 shares of common stock at $3.50 per share. The offer was significantly oversubscribed, with 4,907,881 shares tendered, resulting in a proration factor of approximately 3.47%.
🚩 Red Flags
- Significant oversubscription suggests high demand for liquidity or a perceived price discrepancy between market and tender offer.
📋 Key Facts
- Tender offer price: $3.50 per share in cash.
- Total shares offered for purchase: 300,000 shares.
- Total shares tendered: 4,907,881 shares (oversubscribed).
- Aggregate cost of accepted shares: approximately $1.05 million.
- Proration factor: 3.47392% (except for odd lots which were accepted in full).
- Shares accepted represent ~0.73% of outstanding shares as of Jan 26, 2026.
Anebulo Pharmaceuticals announced the preliminary results of a tender offer to repurchase up to 300,000 shares at $3.50 per share. The offer was significantly oversubscribed, with approximately 4.89 million shares tendered.
🚩 Red Flags
- Significant oversubscription suggests a large portion of shareholders may be looking to exit their positions at the current price level.
📋 Key Facts
- Tender offer price: $3.50 per share in cash.
- Total shares offered for purchase: 300,000 shares.
- Total shares tendered: 4,897,188 shares (excluding guaranteed delivery).
- The offer was oversubscribed with a preliminary proration factor of approximately 3.51542%.
- Aggregate cost for the company is approximately $1.05 million.
- Tender offer expired on January 26, 2026.
Anebulo Pharmaceuticals entered into a $15 million private placement with 22NW Fund, LP, an entity controlled by Director Aron English. This transaction results in Mr. English gaining voting power over more than 50% of the company's common stock, triggering a change in control.
🚩 Red Flags
- Related-party transaction: The primary investor is controlled by a sitting Director.
- Change in control: A director now holds majority voting power (>50%).
- Potential dilution: Issuance of over 15 million shares at the Nasdaq minimum price.
- Registration requirement: Company must register these shares for resale, creating potential future selling pressure.
📋 Key Facts
- Private placement of 15,151,514 shares at $0.99 per share (Nasdaq Minimum Price).
- Aggregate gross proceeds of approximately $15 million.
- 22NW Fund, LP is a greater than 5% stockholder controlled by Director Aron English.
- Transaction results in Mr. English holding >50% of all issued and outstanding shares.
- Company will file a registration statement for the resale of these shares within 60 days.
- The company is modifying its Loan and Security Agreement (LSA) with 22NW to reduce maximum loan size to ~$3 million.
Anebulo Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release and business update for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and a business update.
- Company is an emerging growth company.
Anebulo Pharmaceuticals, Inc. has updated its Corporate Presentation to provide investors with current information regarding the company's operations and outlook.
📋 Key Facts
- The filing is an update to the Company's Corporate Presentation dated October 17, 2024.
- The presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure).
- The information provided in the presentation is not considered 'filed' for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
Anebulo Pharmaceuticals, Inc. issued an 8-K to furnish its quarterly and fiscal year financial results for the period ended June 30, 2024, alongside a general business update.
📋 Key Facts
- Report date: September 25, 2024
- Reporting period covered: Quarter and Fiscal Year ended June 30, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'Emerging Growth Company'
Anebulo Pharmaceuticals announced the receipt of the first tranche of a two-year cooperative grant from the National Institute on Drug Abuse (NIH). The total potential funding is approximately $1.9 million to support the development of intravenous selonabant for treating acute cannabis-induced toxicities.
📋 Key Facts
- Awarded a two-year cooperative grant by the National Institute on Drug Abuse (part of NIH) under award number 1U01DA059995-01.
- Total potential funding is approximately $1.9 million.
- Funding is structured in two tranches: an initial $0.9 million and a subsequent ~$1 million subject to milestones.
- The grant supports the development of intravenous selonabant for emergency treatment of acute cannabis-induced toxicities (including CNS depression in children).
Anebulo Pharmaceuticals, Inc. announced the Board's approval of a new non-employee director equity compensation policy. The policy establishes both initial and annual stock option grants for non-employee directors to align their interests with shareholders.
📋 Key Facts
- Board approved a new 'Director Equity Compensation Policy' on June 13, 2024.
- Initial award: Option to purchase 50,000 shares of common stock per director, vesting pro rata monthly over three years.
- Annual award: Option to purchase 25,000 shares of common stock per director, vesting on the one-year anniversary or at the next annual meeting.
Anebulo Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024 and provide a general business update.
📋 Key Facts
- The filing pertains to financial results for the quarter ended March 31, 2024.
- The company issued a press release (Exhibit 99.1) containing its quarterly earnings and business update.
- The report was filed on May 15, 2024.
Anebulo Pharmaceuticals, Inc. issued an 8-K to announce its financial results for the quarter ended December 31, 2023, and provided a general business update.
📋 Key Facts
- Report date: February 13, 2024
- Reporting period: Quarter ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Company is an emerging growth company.